Vascular endothelial growth factor-A and drug level in serum and human breast milk of a lactating woman after intravitreal injection of ranibizumab: a case report [PDF]
Frontiers in MedicineBackgroundEvidence on the excretion of anti-VEGF drugs in human breast milk was very limited. Here we investigated the level of VEGF-A protein and free drug concentration of ranibizumab in serum and breast milk following intravitreal injection of ...
Jiaxuan Zhang +5 more
doaj +2 more sources
The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery
Drug Delivery, 2022 The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond.
Shrirang V Ranade +2 more
exaly +3 more sources
Journal of International Medical Research, 2020 Objective To compare the efficacy of ranibizumab plus fufang xueshuantong capsule (cFXST) with the efficacy of ranibizumab alone in treatment of exudative age-related macular degeneration.
Hai-Tao Pan, Qing-Huai Liu
exaly +2 more sources
Efficacy of Combining Intravitreal Injections of Ranibizumab with Micropulse Diode Laser versus Intravitreal Injections of Ranibizumab Alone in Diabetic Macular Edema [PDF]
Al-Azhar International Medical Journal, 2023 Background: Diabetes mellitus problems lead to diabetes retinopathy (DRP) and diabetic macular edoema (DME), two retinal disorders.Aim of the study: the study designed to assess effectiveness of intravitreal ranibizumab injections versus intravitreal ...
ahmed omran +2 more
doaj +1 more source
Canadian Medical Association Journal, 2011 Ranibizumab is a recombinant, monoclonal antibody fragment that inhibits vascular endothelial growth factor (known as a VEGF-A inhibitor).1 Because it costs about 10 times more than bevacizumab,2 an anti-VEGF agent approved for intravenous use in metastatic colon cancer, ophthalmologists may ...
Jason, Noble, Varun, Chaudhary
openaire +2 more sources
Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.
PLoS ONE, 2022 PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro.MethodsIn vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced ...
Yusuke Ichiyama +7 more
doaj +1 more source
Inhibitory effect of tenomodulin versus ranibizumab on in vitro angiogenesis [PDF]
International Journal of Ophthalmology, 2017 AIM: To evaluate anti-angiogenic effect of tenomodulin (TNMD) and ranibizumab on cell proliferation and capillary-like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor (VEGF) in vitro.
Wei Wang +4 more
doaj +1 more source
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome [PDF]
International Journal of Ophthalmology, 2016 AIM: To compare visual acuity and central macular thickness (CMT) changes in neovascular age related macular degeneration patients treated with either 6 weekly bevacizumab regimen or 4 weekly ranibizumab on an as required basis.
Patrick J Chiam +3 more
doaj +1 more source
One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study [PDF]
International Journal of Ophthalmology, 2018 AIM: To assess the effectiveness and safety of ranibizumab 0.5 mg in Taiwanese patients with polypoidal choroidal vasculopathy (PCV) by performing a retrospective exploratory subgroup analysis of the REAL study.
San-Ni Chen +8 more
doaj +1 more source
Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. [PDF]
PLoS ONE, 2014 Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the
Paul Mitchell +9 more
doaj +1 more source